Apremilast in combination to narrowband UVB in the treatment of vitiligo. A 52 weeks monocentric prospective randomized placebo-controlled study

Scientific rationale and encouraging first clinical results suggest the interest of using apremilast for treating vitiligo.

Source: Journal of Investigative Dermatology - January 27, 2020 Category: Dermatology Authors: Abdallah Khemis, Eric Fontas, Sophie Moulin, Henri Montaudi é, Jean-Philippe Lacour, Thierry Passeron Tags: Original Article Source Type: research